Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharma Advanced Research | BSE | Salute | Prodotti farmaceutici | 4,26 Bln INR | 38,5x | 1,3 | 1.775,20 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17,6% Rialzo | Fai l’upgrade a Pro+ | |
Sun Pharma AR | NSE | Salute | Prodotti farmaceutici | 4,26 Bln INR | 38,5x | 1,3 | 1.777,25 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17,8% Rialzo | Fai l’upgrade a Pro+ | |
Divis Laboratories | BSE | Salute | Prodotti farmaceutici | 1,57 Bln INR | 85,3x | 2,2 | 5.896,15 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -4,5% Ribasso | Fai l’upgrade a Pro+ | |
Divis Laboratories | NSE | Salute | Prodotti farmaceutici | 1,57 Bln INR | 85,3x | 2,2 | 5.900,85 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -4,6% Ribasso | Fai l’upgrade a Pro+ | |
Cipla | NSE | Salute | Prodotti farmaceutici | 1,19 Bln INR | 26,5x | 0,92 | 1.471,55 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 12,6% Rialzo | Fai l’upgrade a Pro+ | |
Cipla | BSE | Salute | Prodotti farmaceutici | 1,19 Bln INR | 26,5x | 0,92 | 1.471,35 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 12,1% Rialzo | Fai l’upgrade a Pro+ | |
Torrent Pharmaceuticals | NSE | Salute | Prodotti farmaceutici | 1,05 Bln INR | 58,1x | 1,71 | 3.094,85 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17% Rialzo | Fai l’upgrade a Pro+ | |
Torrent Pharmaceuticals | BSE | Salute | Prodotti farmaceutici | 1,05 Bln INR | 58,1x | 1,71 | 3.094,80 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17% Rialzo | Fai l’upgrade a Pro+ | |
Mankind Pharma | BSE | Salute | Prodotti farmaceutici | 1,03 Bln INR | 50,2x | 1,38 | 2.568 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 12,1% Rialzo | Fai l’upgrade a Pro+ | |
Mankind Pharma | NSE | Salute | Prodotti farmaceutici | 1,03 Bln INR | 50,2x | 1,38 | 2.574,40 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 11,8% Rialzo | Fai l’upgrade a Pro+ | |
Dr Reddy’s Laboratories | BSE | Salute | Prodotti farmaceutici | 1,01 Bln INR | 19x | 4,13 | 1.213,95 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 9,6% Rialzo | Fai l’upgrade a Pro+ | |
Dr Reddy’s Laboratories | NSE | Salute | Prodotti farmaceutici | 1,01 Bln INR | 19x | 4,13 | 1.213,45 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 9,6% Rialzo | Fai l’upgrade a Pro+ | |
Max Healthcare Institute | BSE | Salute | Fornitori e servizi sanitari | 969,31 Mrd INR | 99,9x | 14,06 | 997,10 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14,3% Rialzo | Fai l’upgrade a Pro+ | |
Max Healthcare Institute | NSE | Salute | Fornitori e servizi sanitari | 969,31 Mrd INR | 99,9x | 14,06 | 997,80 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14,3% Rialzo | Fai l’upgrade a Pro+ | |
Apollo Hospitals | BSE | Salute | Fornitori e servizi sanitari | 961,47 Mrd INR | 80,3x | 1,16 | 6.681,60 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 21,8% Rialzo | Fai l’upgrade a Pro+ | |
Apollo Hospitals | NSE | Salute | Fornitori e servizi sanitari | 961,47 Mrd INR | 80,3x | 1,16 | 6.686,90 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 21,7% Rialzo | Fai l’upgrade a Pro+ | |
Zydus Lifesciences | BSE | Salute | Prodotti farmaceutici | 953,51 Mrd INR | 22,2x | 0,42 | 946,90 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14,5% Rialzo | Fai l’upgrade a Pro+ | |
Zydus Lifesciences | NSE | Salute | Prodotti farmaceutici | 953,51 Mrd INR | 22,2x | 0,42 | 947,60 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14,4% Rialzo | Fai l’upgrade a Pro+ | |
Lupin | NSE | Salute | Prodotti farmaceutici | 929,82 Mrd INR | 35,4x | 0,36 | 2.038,20 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,8% Rialzo | Fai l’upgrade a Pro+ | |
Lupin | BSE | Salute | Prodotti farmaceutici | 929,82 Mrd INR | 35,4x | 0,36 | 2.037,05 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 11,4% Rialzo | Fai l’upgrade a Pro+ | |
Aurobindo Pharma | BSE | Salute | Prodotti farmaceutici | 726,06 Mrd INR | 20,4x | 0,37 | 1.247,90 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24,2% Rialzo | Fai l’upgrade a Pro+ | |
Aurobindo Pharma | NSE | Salute | Prodotti farmaceutici | 726,06 Mrd INR | 20,4x | 0,37 | 1.250,10 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24% Rialzo | Fai l’upgrade a Pro+ | |
Alkem Laboratories Ltd BO | BSE | Salute | Prodotti farmaceutici | 661,17 Mrd INR | 31,1x | 0,65 | 5.525,25 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,3% Rialzo | Fai l’upgrade a Pro+ | |
Alkem Laboratories Ltd | NSE | Salute | Prodotti farmaceutici | 661,17 Mrd INR | 31,1x | 0,65 | 5.529,80 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,3% Rialzo | Fai l’upgrade a Pro+ | |
Abbott India Ltd | BSE | Salute | Prodotti farmaceutici | 578,50 Mrd INR | 45x | 2,41 | 27.193,80 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,3% Rialzo | Fai l’upgrade a Pro+ | |
Abbott India Ltd | NSE | Salute | Prodotti farmaceutici | 578,50 Mrd INR | 45x | 2,41 | 27.224,35 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,2% Rialzo | Fai l’upgrade a Pro+ | |
Fortis Healthcare (India) | BSE | Salute | Fornitori e servizi sanitari | 496,61 Mrd INR | 75,7x | 3,7 | 657,70 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 8% Rialzo | Fai l’upgrade a Pro+ | |
Fortis Healthcare (India) | NSE | Salute | Fornitori e servizi sanitari | 496,61 Mrd INR | 75,7x | 3,7 | 657,80 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 7,9% Rialzo | Fai l’upgrade a Pro+ | |
Glenmark Pharmaceuticals | NSE | Salute | Prodotti farmaceutici | 421,21 Mrd INR | -48,1x | 0,05 | 1.492,65 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 15,6% Rialzo | Fai l’upgrade a Pro+ | |
Glenmark Pharmaceuticals | BSE | Salute | Prodotti farmaceutici | 421,21 Mrd INR | -48,1x | 0,05 | 1.492,35 INR | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 15,6% Rialzo | Fai l’upgrade a Pro+ |